M
Michael L. Knight
Researcher at University of Oxford
Publications - 27
Citations - 1764
Michael L. Knight is an academic researcher from University of Oxford. The author has contributed to research in topics: Antibody & Epitope. The author has an hindex of 13, co-authored 27 publications receiving 875 citations.
Papers
More filters
Journal ArticleDOI
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
J. Huo,J. Huo,A. Le Bas,A. Le Bas,Reinis R. Ruza,Duyvesteyn Hme.,H. Mikolajek,Tomas Malinauskas,Tiong Kit Tan,Pramila Rijal,Pramila Rijal,Maud Dumoux,Philip N. Ward,Philip N. Ward,Jingshan Ren,D. Zhou,Peter J. Harrison,Peter J. Harrison,Miriam Weckener,Daniel K. Clare,V K Vogirala,Julika Radecke,Lucile Moynié,Yuguang Zhao,Javier Gilbert-Jaramillo,Michael L. Knight,Julia A. Tree,Karen R. Buttigieg,Naomi Coombes,Michael J. Elmore,Miles W. Carroll,Loic Carrique,Shah Pnm.,William James,Alain Townsend,Alain Townsend,David I. Stuart,Raymond J. Owens,Raymond J. Owens,James H. Naismith,James H. Naismith +40 more
TL;DR: Two nanobodies that bind SARS-CoV-2 spike RBD are shown to block interaction with receptor ACE2 and thus neutralize the virus, and have an additive effect with antibody CR3022.
Journal ArticleDOI
The antigenic anatomy of SARS-CoV-2 receptor binding domain.
Wanwisa Dejnirattisai,D. Zhou,Helen M. Ginn,Helen M. E. Duyvesteyn,Piyada Supasa,James Brett Case,Yuguang Zhao,Thomas S. Walter,Alexander J. Mentzer,Chang Liu,Beibei Wang,Guido C. Paesen,J Slon-Campos,Cesar Lopez-Camacho,Natasha M. Kafai,Adam L. Bailey,Rita E. Chen,Baoling Ying,Craig Thompson,Jai S Bolton,Alex Fyfe,Sunetra Gupta,Tiong Kit Tan,Javier Gilbert-Jaramillo,William James,Michael L. Knight,Miles W. Carroll,Donal T. Skelly,Christina Dold,Yanchun Peng,R Levin,Tao Dong,Andrew J. Pollard,Julian C. Knight,Paul Klenerman,Nigel J. Temperton,David R. Hall,Mark A. Williams,Neil G. Paterson,Felicity K.R. Bertram,C. Alistair Siebert,Daniel K. Clare,Andy G. Howe,Julika Radecke,Yun Song,Alain Townsend,Kuan-Ying A. Huang,Elizabeth E. Fry,Juthathip Mongkolsapaya,Juthathip Mongkolsapaya,Michael S. Diamond,Jingshan Ren,David I. Stuart,Gavin R. Screaton +53 more
TL;DR: In this paper, the authors identify 377 human monoclonal antibodies (mAbs) recognizing the virus spike and focus mainly on 80 that bind the receptor binding domain (RBD) and devise a competition data-driven method to map RBD binding sites.
Journal ArticleDOI
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
D. Zhou,Duyvesteyn Hme.,Chen C-P.,Huang C-G.,Huang C-G.,Chen T-H.,Shih S-R.,Shih S-R.,Lin Y-C.,Cheng C-Y.,Cheng S-H.,Huang Y-C.,Lin T-Y.,Che Ma,J. Huo,J. Huo,Loic Carrique,Tomas Malinauskas,Reinis R. Ruza,Shah Pnm.,Tiong Kit Tan,Pramila Rijal,Pramila Rijal,R F Donat,Kerry J Godwin,Karen R. Buttigieg,Julia A. Tree,Julika Radecke,Neil G. Paterson,P Supasa,Juthathip Mongkolsapaya,Juthathip Mongkolsapaya,Gavin R. Screaton,Miles W. Carroll,Miles W. Carroll,Javier Gilbert-Jaramillo,Michael L. Knight,William James,Raymond J. Owens,Raymond J. Owens,James H. Naismith,James H. Naismith,Alain Townsend,Alain Townsend,Elizabeth E. Fry,Yuguang Zhao,Jingshan Ren,David I. Stuart,Huang K-Ya.,Huang K-Ya. +49 more
TL;DR: EY6A, a neutralizing antibody isolated from a patient convalescing from COVID-19, binds the receptor binding domain of the SARS-CoV-2 spike glycoprotein with high affinity, at a location away from the binding site for the ACE2 receptor, similar to the one recognized by CR3022.
Journal ArticleDOI
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Donal T. Skelly,Adam Harding,Javier Gilbert-Jaramillo,Michael L. Knight,S Longet,S Longet,Anthony Brown,S Adele,Emily Adland,Harriet R. Brown,T Tipton,T Tipton,L Stafford,Alexander J. Mentzer,S A Johnson,Ali Amini,Tiong Kit Tan,Lisa Schimanski,Huang K-Ya.,Pramila Rijal,Cmore,John Frater,P Goulder,Christopher P. Conlon,Katie Jeffery,Christina Dold,Andrew J. Pollard,Alex Sigal,Alex Sigal,T de Oliveira,T de Oliveira,Alain Townsend,Paul Klenerman,Susanna Dunachie,E Barnes,Miles W. Carroll,Miles W. Carroll,William James +37 more
TL;DR: In this article, the extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is investigated.
Journal ArticleDOI
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.
Monique Andersson,Carolina V. Arancibia-Cárcamo,Kathryn Auckland,J Kenneth Baillie,Eleanor Barnes,Tom Beneke,Sagida Bibi,Tim Brooks,Miles W. Carroll,Derrick W. Crook,Kate E. Dingle,Christina Dold,Louise O Downs,Laura Dunn,David W Eyre,Javier Gilbert Jaramillo,Heli Harvala,Sarah Hoosdally,Samreen Ijaz,Tim James,William James,Katie Jeffery,Anita Justice,Paul Klenerman,Julian C. Knight,Michael L. Knight,Xu Liu,Sheila F Lumley,Philippa C Matthews,Anna L McNaughton,Alexander J. Mentzer,Juthathip Mongkolsapaya,Sarah Oakley,Marta S Oliveira,Marta S Oliveira,Tim E. A. Peto,Rutger J. Ploeg,Jeremy Ratcliff,Melanie J. Robbins,David J. Roberts,Justine K. Rudkin,Rebecca A. Russell,Gavin R. Screaton,Malcolm G Semple,D T Skelly,Peter Simmonds,Nicole Stoesser,Lance Turtle,Susan Wareing,Maria Zambon +49 more
TL;DR: In this article, the authors conducted a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics, finding that vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used).